DiaGenic ASA Patent Allowed in Canada
4/11/2013 12:21:49 PM
OSLO, Norway--(BUSINESS WIRE)--Regulatory News: DiaGenic (OSE:DIAG) has received notice of allowance for its Canadian family 2 patent application. The allowed claims cover the use of a set of gene sequences in blood essential for the diagnosis of, among other diseases, Alzheimer’s disease and stages thereof. The patent when granted will be valid until 2023.
comments powered by